Sponsored content is premium paid-for content produced by our Content Studio on behalf of commercial clients. Our newsroom or other editorial departments are not involved in the production of sponsored content.
Boston Scientific Cork has completed a remarkable recovery over the past number of years.
“In 2013, our global company sold a business division that Cork was heavily invested in,” says vice president of operations Sean Gayer.
“Approximately half the site’s business was included in the sale of the neuro- vascular business to Stryker.
“In 2020, the site is back to business levels prior to the divestiture and we now employ over 1,000 people again, thanks to the growth experienced over the past number of years.”
The Cork team is very proud of the impact its products have on patients.
The site will produce over 12 million devices in 2020, which are used in the treatment of cancer, blocked arteries, digestive disorders and asthma.
These devices will positively impact 21 patient lives every minute from the products shipped out of Model Farm Road, Cork.
“Patient care is at the centre of everything that we do, and it remains the guiding priority of the organisation,” said Mr Gayer.
Last year, one UK-based surgeon visited the site to personally thank the manufacturing team for producing a catheter product that saved his patient’s life, when the initial outlook was very bleak.
"The story was really powerful, and it emphasised to us the importance of constantly producing quality products to meet our patients’ needs,” said Mr Gayer.
The entire Cork team has contributed to the achievements of the plant: “We have 10,000 years of knowledge coming on site every day and this is our most significant asset.”
Every employee strives to improve their work in an open and honest environment where trust and respect prevails, to better serve the physicians and patients who depend on products being available, when required.
New products have played a key role in the Cork site returning to current business levels as 20 products were launched to the market over the past five years.
These products have introduced leading-edge innovative medical device technologies to the site in areas such as electrical ablation, hydrogel chemistry and automation assembly.
The Cork site was recently awarded an internal CEO Winning Spirit Award for a significant production automation project, which was successfully completed in 2019.
This award comes after the Shingo Gold Prize for Operational Excellence received in 2016 and the Cork Company of the Year award in 2018.
The company also has a number of key employee resource groups that contribute enormously to the site culture.
The four groups are: Women’s Network; Young Professionals Network; Promoting Respect, Inclusion, Diversity and Equality; and Leadership, Education and Allies for Disabilities.
“We want people to authentically bring their whole self to work and these groups do great work in that regard,” said Mr Gayer.
The company’s charity team continues its work of raising over €40,000 for its employee-selected charity of the year.
In 2019, the company’s charity was Cork City Missing Persons Search and Recovery, which is a truly amazing group of people, when you consider what they do for the community on a voluntary basis.
The 2020 charity partner is Down Syndrome Centre Cork. The Cork site has a strong environmental focus. It is accredited with ISO 14001 and ISO 50001.
The site has an active green team which engages all employees in environmental projects such as coastal clean ups and education on recycling programmes during the year.
Mr Gayer says the American Chamber of Commerce in Ireland continues to be a very strong voice for US companies in Ireland, by highlighting business challenges and making constructive, progressive representations on our behalf.
The networking opportunities allow for engagement and best practice sharing in multiple sectors.
Boston Scientific came to Cork in 1997 and shipped its first product in 1998.
The journey to date has been eventful but thanks to the growth over the past number of years, the planned future investment and the continued strong new product pipeline, the future journey looks equally interesting.